Intravenous iron in heart failure: Beyond targeting anemia

Current Heart Failure Reports

Volumn 8, Issue 1, 2011, Pages 14-21

  Silverberg, Donald S ^a   Iaina, Adrian ^a   Schwartz, Doron ^a   Wexler, Dov ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Cardiorenal anemia syndrome; Erythropoietin; Heart failure; Iron; Renal failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; INTERLEUKIN 4; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DRUG SAFETY; EXERCISE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON METABOLISM; KIDNEY FUNCTION; PATIENT ASSESSMENT; QUALITY OF LIFE;

ANEMIA, IRON-DEFICIENCY; FERRIC COMPOUNDS; HEART FAILURE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 79551543821     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0034-4     Document Type: Article

References (62)

1. SR Gandra FO Finkelstein AV Bennett, et al. 2010 Impact of erythropoiesis-stimulating agents on energy and physical function in non-dialysis CKD patients with anemia: a systematic review Am J Kidney Dis 55 519 534 1:CAS:528:DC%2BC3cXksVynurc%3D 20031287 10.1053/j.ajkd.2009.09.019
2. KL Johansen FO Finkelstein DA Revicki, et al. 2010 Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents Am J Kidney Dis 55 535 548 1:CAS:528:DC%2BC3cXksVynu74%3D 20133033 10.1053/j.ajkd.2009.12.018
3. HF Groenveld JL Januzzi K Damman, et al. 2008 Anemia and mortality in heart failure patients: a systematic review and meta-analysis J Am Coll Cardiol 52 818 827 18755344 10.1016/j.jacc.2008.04.061 This article emphasizes the high prevalence of anemia in CHF and its independent contribution to mortality
4. SW He LX Wang 2009 The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review Congest Heart Fail 15 123 130 19522961 10.1111/j.1751-7133.2008.00030.x This article summarizes the increased risks of anemia in CHF
5. •• Ngo K, Kotecha D, Walters JA, et al.: Erythropoiesis- stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010, (1):CD007613. This is an extensive meta-analysis on the effects of treatment of erythropoiesis-stimulating agents in CHF.
6. P van der Meer H Groenveld JL Januzzi Jr 2009 van Veldhuisen DJ: Erythropoietin treatment in patients with Chronic Heart Failure: a meta-analysis Heart 95 1309 1314 19168472 10.1136/hrt.2008.161091
7. B Jin X Luo H Lin, et al. 2010 A meta-analysis of erythropoiesis- stimulating agents in anaemic patients with chronic heart failure Eur J Heart Fail 12 249 253 1:CAS:528:DC%2BC3cXitlejsr8%3D 20031949 10.1093/eurjhf/hfp182
8. F Tehrani P Dhesi B Daneshvar, et al. 2009 Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis Cardiovasc Drugs Ther 23 511 518 1:CAS:528:DC%2BC3cXjtl2htw%3D%3D 19862609 10.1007/s10557-009- 6203-6
9. A Desai E Lewis S Solomon, et al. 2010 Impact of erythropoiesis- stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT metaanalysis Eur J Heart Fail 12 936 942 20525985 10.1093/eurjhf/hfq094
10. JJ McMurray IS Anand R Diaz, et al. 2009 Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail 11 795 801 1:CAS:528:DC%2BD1MXptFCnsbY%3D 19633103 10.1093/eurjhf/hfp098
11. D Goldsmith 2010 2009: a requiem for rHuEPOs-but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 5 929 935 1:CAS:528:DC%2BC3cXnsVyrur8%3D 20413441 10.2215/CJN.09131209
12. EF Unger AM Thompson MJ Blank R Temple 2010 Erythropoiesis-stimulating agents: time for a reevaluation N Engl J Med 362 189 192 1:CAS:528: DC%2BC3cXosV2iug%3D%3D 20054037 10.1056/NEJMp0912328
13. AK Singh 2010 Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21 2 6 20035034 10.1681/ASN.2009111127
14. J Bohlius K Schmidlin C Brillant, et al. 2009 Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials Lancet 373 1532 1543 1:CAS:528: DC%2BD1MXltlaqurg%3D 19410717 10.1016/S0140-6736(09)60502-X Published erratum appears in Lancet 2009, 374:28
15. CL Bennett SM Silver B Djulbegovic, et al. 2008 Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 299 914 924 1:CAS:528:DC%2BD1cXis1Cns7s%3D 18314434 10.1001/jama.299.8.914 (Pubitemid 351397066)
16. E Streja CP Kovesdy S Greenland, et al. 2008 Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis Am J Kidney Dis 52 727 736 1:CAS:528:DC%2BD1cXht1yisb3K 18760517 10.1053/j.ajkd.2008.05.029
17. ND Vaziri XJ Zhou 2009 Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol Dial Transplant 24 1082 1088 1:CAS:528:DC%2BD1MXjsFeks7w%3D 18987263 10.1093/ndt/gfn601 This is a broad review of the biochemical and physiological effects of erythropoietin
18. CL Murphy RJ Fitzimmons AJ Jardine, et al. 2007 Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anemia Eur J Heart Fail Suppl 6 Suppl 103
19. EA Jankowska P Rozentryt A Witkowska, et al. 2010 Iron deficiency: an ominous sign in patients with systolic heart failure Eur Heart J 31 1872 1880 1:CAS:528:DC%2BC3cXpsFOitLw%3D 20570952 10.1093/eurheartj/ehq158
20. R de Silva AS Rigby KK Witte, et al. 2006 Anemia, renal dysfunction, and their interaction in patients with chronic heart failure Am J Cardiol 98 391 398 16860030 10.1016/j.amjcard.2006.01.107 (Pubitemid 44062453)
21. C Opasich M Cazzola L Scelsi, et al. 2005 Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of in patients with chronic heart failure Eur Heart J 26 2232 2237 1:CAS:528:DC%2BD2MXht1Kku73I 15987710 10.1093/eurheartj/ehi388 (Pubitemid 41541385)
22. JN Nanas C Matsouka D Karageorgopoulos, et al. 2006 Etiology of anemia in patients with advanced heart failure J Am Coll Cardiol 48 2485 2489 17174186 10.1016/j.jacc.2006.08.034 (Pubitemid 44881220)
23. JE Toblli A Lombraña P Duarte F Di Gennaro 2007 Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency J Am Coll Cardiol 50 1657 1665 1:CAS:528:DC%2BD2sXhtF2qsr%2FP 17950147 10.1016/j.jacc.2007.07.029 This is a small but well-done placebo-controlled study to show the many effects of intravenous iron in patients with CHF (Pubitemid 47562670)
24. SD Anker J Comin Colet G Filippatos, et al. 2009 Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2436 2448 1:CAS:528:DC%2BD1MXhsFKisr7K 19920054 10.1056/NEJMoa0908355 This is a landmark, large, placebo-controlled, multicenter study on the effects of intravenous iron in CHF
25. DO Okonko A Grzeslo T Witkowski, et al. 2008 Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial J Am Coll Cardiol 51 103 112 1:CAS:528: DC%2BD1cXlsFeqsg%3D%3D 18191732 10.1016/j.jacc.2007.09.036
26. AP Bolger FP Bartlett HS Penston, et al. 2006 Intravenous iron alone for the treatment of anemia in patients with chronic heart failure J Am Coll Cardiol 48 1225 1227 1:CAS:528:DC%2BD28Xps1Citro%3D 16979010 10.1016/j.jacc.2006.07.015 (Pubitemid 44345150)
27. RI Usmanov EB Zueva DS Silverberg M Shaked 2008 Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency J Nephrol 21 236 242 1:CAS:528:DC%2BD1cXht12qsrvI 18446719
28. SG Drakos MI Anastasiou-Nana KG Malliaras JN Nanas 2009 Anemia in chronic heart failure Congest Heart Fail 15 87 92 1:CAS:528:DC%2BD1MXls1yqt78%3D 19379455 10.1111/j.1751-7133.2009.00049.x
29. A Palazzuoli D Silverberg F Iovine, et al. 2006 Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia Am Heart J 152 1096.e9 1096.e15 10.1016/j.ahj.2006.08.005 (Pubitemid 44854798)
30. CY Hsu CE McCulloch GC Curhan 2002 Iron status and hemoglobin level in chronic renal insufficiency J Am Soc Nephrol 13 2783 2786 1:CAS:528: DC%2BD38XnvF2lsL4%3D 12397050 10.1097/01.ASN.0000034200.82278.DC (Pubitemid 35216049)
31. F Valderrábano WH Hörl IC Macdougall, et al. 2003 PRE-dialysis survey in anaemia management Nephrol Dial Transplant 18 89 100 12480965 10.1093/ndt/18.1.89 (Pubitemid 36104483)
32. S Fishbane S Pollack HI Feldman MM Joffe 2009 Iron indices in chronic kidney disease in the National Health and Nutritional Exzmination Survey 1988-2004 Clin J Am Soc Nephrol 4 57 61 1:CAS:528:DC%2BD1MXitVWnur4%3D 18987297 10.2215/CJN.01670408
33. L Gotloib D Silverberg R Fudin A Shostak 2006 Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron J Nephrol 19 161 167 1:CAS:528:DC%2BD2sXhtl2gtbzN 16736414
34. S Stancu A Stanciu A Zugravu, et al. 2010 Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD Am J Kidney Dis 55 639 647 1:CAS:528:DC%2BC3cXlsFSls7Y%3D 20079959 10.1053/j.ajkd.2009.10.043
35. A Sandek M Rauchhaus SD Anker S von Haehling 2008 The emerging role of the gut in chronic heart failure Curr Opin Clin Nutr Metab Care 11 632 639 18685461 10.1097/MCO.0b013e32830a4c6e
36. E Nemeth 2008 Iron regulation and erythropoiesis Curr Opin Hematol 15 169 175 1:CAS:528:DC%2BD1cXltlSnur8%3D 18391780 10.1097/MOH.0b013e3282f73335 (Pubitemid 351507567)
37. G Weiss 2009 Iron metabolism in the anemia of chronic disease Biochim Biophys Acta 1790 682 693 1:CAS:528:DC%2BD1MXnt1yjurw%3D 18786614
38. DR Ashby DP Gale M Busbridge, et al. 2009 Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease Kidney Int 75 976 981 1:CAS:528:DC%2BD1MXks1SjsLc%3D 19212416 10.1038/ki.2009.21
39. C Ronco PA McCullough SD Anker, et al. 2010 Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiation (ADQI) Contrib Nephrol 165 54 67 20427956 10.1159/000313745
40. P Ponka 1999 Cellular iron metabolism. Kidney Int Suppl 69 S2 S11 1:CAS:528:DyaK1MXhvVSnur0%3D 10.1046/j.1523-1755.1999.055Suppl.69002.x
41. Y Naito T Tsujino M Matsumoto, et al. 2009 Adaptive response of the heart to long term anemia induced by iron deficiency Am J Physiol Heart Circ Physiol 296 H585 H593 1:CAS:528:DC%2BD1MXjtFGks78%3D 19136608 10.1152/ajpheart.00463. 2008 This is a careful analysis of the cellular effects of iron deficiency on the heart
42. F Dong X Zhang B Culver, et al. 2005 Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrosome C release: involvement of nitric oxide synthase and protein tyrosine nitration Clin Sci (Lond) 109 277 286 1:CAS:528:DC%2BD2MXoslKgu7s%3D 10.1042/CS20040278 (Pubitemid 41337132)
43. E Beutler 2002 History of iron in medicine Blood Cells Mol Dis 29 297 308 1:CAS:528:DC%2BD3sXlt1yltQ%3D%3D 12547220 10.1006/bcmd.2002.0560
44. Haas JD, Brownlie T 4th: Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001, 131(2S-2):676S-688S
45. F Verdon B Burnand CL Stubi, et al. 2003 Iron supplementation for unexplained fatigue in non-anemic women: double blind randomized placebo controlled trial BMJ 326 1124 1:CAS:528:DC%2BD3sXltFGgu70%3D 12763985 10.1136/bmj.326.7399.1124
46. DB Van Wyck M Roppolo CO Martinez, et al. 2005 A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD Kidney Int 68 2846 2856 16316362 10.1111/j.1523-1755. 2005.00758.x (Pubitemid 43251032)
47. G Mircescu L Gârneata C Capusa N Ursea 2006 Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients Nephrol Dial Transplant 21 120 124 1:CAS:528: DC%2BD28XisFKiug%3D%3D 16144853 10.1093/ndt/gfi087 (Pubitemid 43057119)
48. B Rozen-Zvi A Gafter-Gvili M Paul, et al. 2008 Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis Am J Kidney Dis 52 897 906 1:CAS:528:DC%2BD1cXhsVarsbzN
49. IC Macdougall 2009 Evolution of iv iron compounds over the last century J Ren Care 35 Suppl 2 8 13 19891680 10.1111/j.1755-6686.2009.00127.x This is a useful review of the history and advances in intravenous iron therapy
50. CP Kovesdy K Kalantar-Zadeh 2009 Iron therapy in chronic kidney disease: current controversies J Ren Care 35 Suppl 2 14 24 19891681 10.1111/j.1755-6686. 2009.00125.x This is an extensive review of all aspects of intravenous iron therapy
51. K Bishu R Agarwal 2006 Acute injury with intravenous iron and concerns regarding long-term safety Clin J Am Soc Nephrol 1 Suppl 1 S19 S23 1:CAS:528:DC%2BD28XhtVOnsbrF 17699372 10.2215/CJN.01420406
52. S Stancu L Bârsan A Stanciu G Mircescu 2010 Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5 409 416 1:CAS:528:DC%2BC3cXkslShs7k%3D 20019121 10.2215/CJN.04280609
53. AK Singh DW Cone W Shapiro AR Rizkala 2007 Predictors of the response to treatment in anemic hemodialysis patients with elevated ferritin Kidney Int 71 1163 1171 1:CAS:528:DC%2BD2sXls1Kjsr4%3D 17396118 10.1038/sj.ki.5002223 (Pubitemid 46809141)
54. DW Coyne T Kapoian W Suki, et al. 2007 Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J Am Soc Nephrol 18 975 984 1:CAS:528:DC%2BD2sXjs1Grsb8%3D 17267740 10.1681/ASN.2006091034 (Pubitemid 46434515)
55. K Kalantar-Zadeh DL Regidor CJ McAllister, et al. 2005 Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 16 3070 3080 1:CAS:528:DC%2BD2MXhtFegtLbO 16033854 10.1681/ASN. 2005040423 (Pubitemid 44743505)
56. HI Feldman M Joffe B Robinson, et al. 2004 Administration of parenteral iron and mortality among hemodialysis patients J Am Soc Nephrol 15 1623 1632 1:CAS:528:DC%2BD2cXktVWiu7s%3D 15153574 10.1097/01.ASN.0000128009.69594.BE (Pubitemid 38679688)
57. VE Pollak JA Lorch R Shukla S Satwah 2009 The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alpha and intravenous iron: analysis of 9.5 years of prospectively collected data BMC Nephrology 10 6 19245700 10.1186/1471-2369-10-6
58. KL Kuo SC Hung YH Wei DC Tarng 2008 Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients J Am Soc Nephrol 19 1817 1826 1:CAS:528:DC%2BD1cXhtFensrnP 18495964 10.1681/ASN.2007101084
59. G Weiss E Meusburger G Radacher, et al. 2003 Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin Kidney Int 64 572 578 1:CAS:528:DC%2BD3sXmsFyrsr4%3D 12846752 10.1046/j.1523-1755.2003.00099.x (Pubitemid 36871928)
60. DS Silverberg D Wexler A Iaina D Schwartz 2009 The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions Clin Exp Nephrol 13 101 106 1:CAS:528:DC%2BD1MXmt1Wltbs%3D 18670732 10.1007/s10157-008-0074-1
61. US Food and Drug Administration: Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). FDA Alert Nov 8, 2007. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm126481.htm http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm. Accesses September 2010.
62. DS Silverberg D Wexler M Blum A Iaina 2003 The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations Clin Nephrology 60 Suppl 1 S93 S102